Sarvoshadhi Biotech Pvt. Ltd. is working in the field of Biotechnology/Life Sciences. It works on developing and supplying cell culture media, feeds and other reagents to Biotechnology and Pharmaceutical Industries thereby supporting them in successful development and commercialization of human therapeutics.
Fluorogent is a spin-off based on NCL’s technology created under Venture Center’s “Lab2Mkt” program. The company wishes to develop fluorescence-based reagents and diagnostic kit useful for quantitative detection of biomarkers such as cysteine and homocysteine, and glutathione (GSH), which play essential roles for regulating the redox balance of many biological processes.
Cysteine is a metabolic product of homocysteine and a precursor of the antioxidant GSH. A deficiency of cysteine leads to diseases such as decreased hematopoiesis (creation of new blood cells), leukocyte loss, psoriasis, slowed growth, liver damage, skin lesions, hair depigmentation, edema, and so on. Elevated levels of homocysterine have been recognized as an independent risk factor for cardiovascular disease. This is also associated with various diseases or clinical conditions, which include Alzheimer’s disease, schizophrenia, end-stage renal disease, osteoporosis, and type II diabetes.
To elucidate the complicated relationship between Cys, Hcy, and GSH and investigate the function of each biothiol in various physiological processes, the simultaneous quantitative detection of these three biothiols is very necessary.
The company has received Biotechnology Ignition Grant by DBT-BIRAC, GoI
ExoCan is the first exosomes based company in India working in the Oncodiagnostic and Therapeutics space. ExoCan is dedicated to build innovative technology platforms in the frontiers of exosomes research by using their propriety technologies. It aims to translate the clinical potential of these tiny vesicles for better management of cancers by employing cross-disciplinary approaches at the forefront of exosomes research. The company is building up a broad range of biofluids e.g. urine, saliva, blood based platforms suitable to end users and clinicians alike. This platforms offer following advantages over existing exosomes based technologies for cancer diagnosis:
1.Rapid, and sensitive method for enriching exosomes from biofluids
2. Enhanced selectivity of the test
3. High yield and precision
4. Choice based use of technology
The company has received Biotechnology Ignition Grant by DBT-BIRAC, GoI, Exocan is founded by Aman Sharma who is persuing his Ph.D from NCCS, Pune